Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?
Nov 02
Have your own idea? Try our Stock Screener
U.K. (FTSE) Biotech Industry Analysis
UpdatedDec 17, 2024
DataAggregated Company Financials
Companies22
- 7D-1.9%
- 3M-5.6%
- 1Y-17.4%
- YTD-22.0%
Over the last 7 days, the Biotech industry has dropped 1.9%, driven by Genus declining 3.0%. In contrast, OptiBiotix Health has gained 41%. Overall the industry is down 17% in 12 months. Looking forward, earnings are forecast to grow by 34% annually.
Industry Valuation and Performance
Has the U.K. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 17 Dec 2024 | UK£2.7b | UK£841.5m | -UK£293,734,272.25 | 79x | -9.1x | 3.2x |
| Thu, 14 Nov 2024 | UK£2.8b | UK£840.8m | -UK£293,945,911.99 | 86.4x | -9.4x | 3.3x |
| Sat, 12 Oct 2024 | UK£2.9b | UK£840.2m | -UK£295,599,113.82 | 97.1x | -10x | 3.5x |
| Mon, 09 Sep 2024 | UK£2.7b | UK£830.5m | -UK£314,446,085.32 | 82.9x | -8.7x | 3.3x |
| Wed, 07 Aug 2024 | UK£2.6b | UK£838.4m | -UK£258,170,344.88 | 30.3x | -10x | 3.1x |
| Fri, 05 Jul 2024 | UK£2.6b | UK£835.6m | -UK£260,791,630.77 | 30.3x | -10.1x | 3.1x |
| Sun, 02 Jun 2024 | UK£3.0b | UK£836.3m | -UK£287,266,028.40 | 30.6x | -10.3x | 3.6x |
| Tue, 30 Apr 2024 | UK£3.2b | UK£895.7m | -UK£215,376,495.24 | 31.2x | -14.7x | 3.5x |
| Thu, 28 Mar 2024 | UK£3.1b | UK£903.1m | -UK£202,126,857.04 | 28.4x | -15.3x | 3.4x |
| Sat, 24 Feb 2024 | UK£3.3b | UK£896.7m | -UK£197,698,774.85 | 32.6x | -16.7x | 3.7x |
| Mon, 22 Jan 2024 | UK£6.4b | UK£1.3b | -UK£245,297,001.00 | 37.3x | -25.9x | 5x |
| Wed, 20 Dec 2023 | UK£6.2b | UK£1.3b | -UK£245,101,181.00 | 37.5x | -25.4x | 4.9x |
| Fri, 17 Nov 2023 | UK£6.5b | UK£1.3b | -UK£242,542,229.00 | 38.6x | -26.6x | 5.1x |
| Sun, 15 Oct 2023 | UK£6.6b | UK£1.3b | -UK£251,303,385.00 | 38.4x | -26.1x | 5.1x |
| Tue, 12 Sep 2023 | UK£6.6b | UK£1.3b | -UK£206,702,008.00 | 23.6x | -31.7x | 5.1x |
| Thu, 10 Aug 2023 | UK£6.8b | UK£1.3b | -UK£207,967,768.00 | 23.6x | -32.5x | 5.4x |
| Sat, 08 Jul 2023 | UK£6.7b | UK£1.3b | -UK£208,510,181.00 | 23.9x | -32.2x | 5.3x |
| Mon, 05 Jun 2023 | UK£7.0b | UK£1.3b | -UK£204,603,564.00 | 22.6x | -34.3x | 5.6x |
| Wed, 03 May 2023 | UK£7.1b | UK£1.3b | -UK£206,395,552.00 | 23.7x | -34.2x | 5.6x |
| Fri, 31 Mar 2023 | UK£7.2b | UK£1.2b | -UK£154,920,420.00 | 24x | -46.2x | 5.8x |
| Sun, 26 Feb 2023 | UK£7.4b | UK£1.2b | -UK£156,977,013.00 | 26.1x | -47.4x | 6x |
| Tue, 24 Jan 2023 | UK£7.6b | UK£1.2b | -UK£140,066,429.00 | 27.6x | -54.6x | 6.6x |
| Thu, 22 Dec 2022 | UK£7.5b | UK£1.2b | -UK£138,236,364.00 | 26.7x | -54x | 6.4x |
| Sat, 19 Nov 2022 | UK£7.8b | UK£1.2b | -UK£139,984,413.00 | 25.1x | -55.6x | 6.7x |
| Mon, 17 Oct 2022 | UK£7.0b | UK£1.2b | -UK£150,681,291.00 | 26.2x | -46.7x | 6.1x |
| Wed, 14 Sep 2022 | UK£7.6b | UK£1.1b | -UK£144,420,164.00 | 35.4x | -52.4x | 6.6x |
| Fri, 12 Aug 2022 | UK£7.5b | UK£1.1b | -UK£200,200,136.00 | 37.6x | -37.3x | 6.7x |
| Sun, 10 Jul 2022 | UK£7.1b | UK£1.1b | -UK£175,037,886.00 | 36.3x | -40.4x | 6.3x |
| Tue, 07 Jun 2022 | UK£7.2b | UK£1.1b | -UK£156,741,499.00 | 38.4x | -46x | 6.5x |
| Thu, 05 May 2022 | UK£7.0b | UK£1.1b | -UK£139,720,661.00 | 34.6x | -50.5x | 6.3x |
| Sat, 02 Apr 2022 | UK£7.4b | UK£1.1b | -UK£87,748,275.00 | 41.5x | -84.2x | 6.8x |
| Mon, 28 Feb 2022 | UK£7.7b | UK£1.1b | -UK£130,231,992.00 | 32.8x | -59.4x | 7.1x |
| Wed, 26 Jan 2022 | UK£8.9b | UK£1.1b | -UK£123,476,632.00 | 40.6x | -72.1x | 8.2x |
| Fri, 24 Dec 2021 | UK£11.2b | UK£1.1b | -UK£120,922,794.00 | 56.8x | -92.9x | 10.3x |
Price to Earnings Ratio
-92.9x
Current Industry PE
- Investors are pessimistic on the British Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.9x is higher than the industry's current PS ratio of 3.2x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 8.2% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | -1.18% | |
| Healthcare | -2.31% | |
| Biotech | -1.91% | |
| Biotech | -1.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SBTX SkinBioTherapeutics | UK£0.19 | 18.8% +UK£6.9m | 19.7% | PS35.9x | |
| AVCT Avacta Group | UK£0.45 | 2.9% +UK£4.6m | -62.0% | PS7.3x | |
| OPTI OptiBiotix Health | UK£0.21 | 28.0% +UK£4.5m | -14.3% | PS36.1x | |
| TRX Tissue Regenix Group | UK£0.59 | 2.6% +UK£1.1m | 10.2% | PS1.7x | |
| ROQ Roquefort Therapeutics | UK£0.043 | 7.5% +UK£387.5k | -38.6% | PB1.1x |